Drug Trial Radar · NCT00680095
Cumulative Irritation Test
Last checked: Nov 20, 2026Latest source record: Apr 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Jan 22, 2007
Primary completion
Feb 19, 2007
Study completion Feb 19, 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.
Conditions
- Onychomycosis
Interventions
AN2690Drug
AN2690 Solution, 2.5%, Daily for up to 21 days
AN2690Drug
AN2690 Solution, 7.5%, Daily for up to 21 days
AN2690Drug
AN2690 Solution, 5.0%, Daily for up to 21 days
AN2690 Solution, VehicleOther
AN2690 Solution, Vehicle, Daily for up to 21 days
Sodium Lauryl Sulfate, 0.5%Other
Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe irritation (Grade 3 or 4) observed at any siteTime frame: Daily for 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Education and Research Foundation, Inc.
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.